Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICALS INTERNATIONAL GMBH”

41 pharma patents match "TEVA PHARMACEUTICALS INTERNATIONAL GMBH" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 41
Index total 30,257
Page 2 / 2

Quick answer

This filtered view shows 41 pharmaceutical patents matching "TEVA PHARMACEUTICALS INTERNATIONAL GMBH" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

41 results for “TEVA PHARMACEUTICALS INTERNATIONAL GMBH” · 30,257 patents in full index Clear search

  1. US 10323085

    Methods of treating fibromyalgia

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 18, 2019 · Expires Jun 13, 2039

    granted
  2. US 10314819

    Solid state forms of Eluxadoline

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted
  3. US 10214553

    Solid state forms of sofosbuvir

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted
  4. US 10188648

    Solid state forms of selexipag

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted
  5. US 9896502

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  6. US 9890210

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  7. US 9890211

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  8. US 9884907

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  9. US 9884908

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  10. US 9814706

    Hydrobromide salt of pridopidine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 14, 2017 · Expires Nov 9, 2037

    granted
  11. US 9796673

    L-tartrate salt of pridopidine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted
  12. US 9763904

    Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  13. US 9682033

    Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  14. US 9592291

    Methods for iontophoretically treating nausea and migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted
  15. US 9427578

    Pharmacokinetics of iontophoretic sumatriptan administration

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Aug 30, 2016 · Expires Aug 25, 2036

    granted
  16. US 9272137

    Transdermal methods and systems for the delivery of anti-migraine compounds

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted
  17. US 9139525

    N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted